CHRM3 and neoplasm: Tumor inhibitory rate in the SC-mPEG20k-HM-3 group (50.23%) and HM-3 group (43.92%) were similar to that in the Taxol group (44.50%), indicating that SC-mPEG20k-HM-3 maintained its anti-tumor activity.